1975 - 1995 Revised anti-cancer serological response: Biological significance and clinical implications

Annals of Oncology

Volumn 7, Issue 3, 1996, Pages 227-232

  Canevari, S ^a   Pupa, S M ^a   Menard S ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Prognosis; Serological response; TAA; Therapy; Vaccination

Indexed keywords

CANCER VACCINE; TUMOR ANTIGEN;

CANCER IMMUNOTHERAPY; HUMAN; PRIORITY JOURNAL; REVIEW; SEROLOGY; TUMOR IMMUNITY;

ANTIBODY FORMATION; HUMANS; IMMUNOTHERAPY, ACTIVE; NEOPLASMS;

EID: 0029921936     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010564     Document Type: Review

References (62)

1. Prehn RT, Main JM. Immunity of methytcholanthrene-induced sarcomas. J Natl Cancer Inst 1957; 18: 769-78.
2. Klein E, Klein G. Antigenic properties of lymphomas induced by the Moloney agent. J Natl Cancer Inst 1964; 32: 547-68.
3. Kripke ML. Antigenicity of murine skin tumors induced by ultraviolet light. J Natl Cancer Inst 1974; 53: 1333.
4. Möller G (ed). Immunological Reviews. Vol. 145: Tumor Immunology. Copenhagen: Munksgaard International Booksellers and Publishers 1995.
5. Cantley LC, Auger KR, Carpenter C et al. Oncogenes and signal transduction. Cell 1991; 64: 281-302.
6. Hakomori S-I. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res 1989; 52; 257-331.
7. Riethmüller G, Schneider-Gädicke E, Schlimok G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994; 343: 1177-83.
8. Mittelman A, Chen GZJ, Wong GY et al. Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Modulation of the immunogenicity in patients with malignant melanoma. Clin Cancer Res 1995; 1: 705-13.
9. Brown SL, Miller RA, Horning SJ et al. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 1989; 73: 651-61.
10. Oettgen HF, Retting WJ, Lloyd KO et al. Serologic analysis of human cancer. Immunol Allergy Clin N Am 1990; 10: 607-37.
11. Old LJ. Cancer immunology: The search for specificity. Cancer Res 1981; 41: 361-75.
12. Sorokine I, Ben-Mahrez K, Bracone A et al. Presence of circulating anti-c-myb oncogene product antibodies in human sera. Int J Cancer 1991; 47: 665-9.
13. Peyrat J-P, Bonneterre J, Lubin R et al. Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 1995; 345: 621-2.
14. Houbiers JGA, Van der Burg SH, Van de Watering LMG et al. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 1995; 72: 637-41.
15. Lubin R, Zalcman G, Bouchet L et al. Serum p53 antibodies as early markers of lung cancer. Nature Med 1995; 1: 701-2.
16. Cheever MA, Disis ML, Bernhard H et al. Immunity to oncogenic proteins. Immunol Rev 1995; 145: 33-59.
17. Gourevitch MM, von Mensdorff-Pouilly S, Litvinov SV et al. Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Br J Cancer 1995; 72: 934-8.
18. Pupa SM, Ménard S, Andreola S et al. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res 1993; 53: 5864-6.
19. Pupa SM, Ménard S, Morelli D et al. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 1993; 8: 2917-23.
20. Winter SF, Sekido Y, Minna JD et al. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: Association with improved survival. J Natl Cancer Inst 1993; 85: 2012-8.
21. Lloyd KO. Humoral immune responses to tumor-associated carbohydrate antigens. Semin Cancer Biol 1991; 2: 421-31.
22. Sahin U, Tureci O, Schmitt H et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995; 92: 11810-3.
23. Himmelweit, F. The Collected Papers of Paul Ehrlich. New York: Pergamon Press 1960; Vol. 3.
24. Silverstein AM. The concept of immunological specificity. In Harcourt BJ (ed): A History of Immunology. San Diego: Academic Press 1989.
25. Cohen J. Cancer vaccines get a shot in the arm. Science 1993; 262: 841-3.
26. Livingston PO, Wong GYC, Adluri S et al. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 12: 1036-44.
27. Livingston PO. Augmenting the immunogenicity of carbohydrate tumor antigens. Semin Cancer Biol 1996; in press.
28. Kennedy RC, Zhou E-M, Lanford RE et al. Possible role of anti-idiotypic antibodies in the induction of tumor immunity. J Clin Invest 1987; 80: 1217-24.
29. Nepom GT, Hellström KE. Anti-idiotypic antibodies and the induction of specific tumor immunity. Cancer Metastasis Rev 1987; 6: 489-502.
30. Chen ZJ, Yang H, Ferrone S. Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Characterization of the immunogenicity in syngeneic hosts. J Immunol 1991; 147: 1082-90.
31. Fagerberg J, Steinitz M, Wigzell H et al. Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Natl Acad Sci USA 1995; 92: 4773-7.
32. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother 1994; 15: 42-52.
33. Baum RP, Niesen A, Hertel A et al. Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer 1994; 73 (Suppl): 1121-5.
34. Muto MG, Lepisto EM, van den Abbeele AD et al. Influence of human antimurine antibody on CA-125 levels in patients with ovarian cancer undergoing radioimmunotherapy or immunoscintigraphy with murine monoclonal antibody OC-125. Am J Obstet Gynecol 1989; 161: 1206-12.
35. Moseley KR, Knapp RC, Haisma HJ. An assay for the detection of human anti-murine immunoglobulins in the presence of CA125 antigen. J Immunol Methods 1988; 106: 1.
36. Manson LA. Does antibody-dependent epitope masking permit progressive tumour growth in the face of cell-mediated cytotoxicity. Immunol Today 1991; 12: 352-5.
37. Figini M, Orlandi R. New techniques for the production of therapeutic recombinant human monoclonal antibodies. Clin Immunother 1995; 4: 301-11.
38. Ben-Mahrez K, Thierry D, Sorokine I et al. Detection of circulating antibodies against c-myc protein in cancer patient sera. Br J Cancer 1988; 57: 529-34.
39. Ben-Mahrez K, Sorokine I, Thierry D et al. Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients. Int J Cancer 1990; 46: 35-8.
40. Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982; 30: 403-8.
41. Caron de Fromentel C, May-Levin F, Mouriesse H et al. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int J Cancer 1987; 39: 185-9.
42. Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 1992; 89: 3439-42.
43. Schlichthotz B, Legros Y, Gillet D et al. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992; 52: 6380-4.
44. Winter SF, Minna JD, Johnson BE et al. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992; 52: 4168-74.
45. Lubin R, Schlichtholz B, Bengoufa D et al. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: Distribution of primary structure and exposure on protein surface. Cancer Res 1993; 53: 5872-6.
46. Labrecque S, Naor N, Thomson D et al. Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 1993; 53: 3468-71.
47. Angelopoulou K, Diamandis EP, Sutherland DJA et al. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994; 58: 480-7.
48. Schlichtholz B, Trédaniel J, Lubin R et al. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 1994; 69: 809-16.
49. Mudenda B, Green JA, Green B et al. The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer 1994; 69: 1115-9.
50. Vojtesek B, Kovarik J, Dolezalova H et al. Absence of p53 autoantibodies in a significant proportion of breast cancer patients. Br J Cancer 1995; 71: 1253-6.
51. Ménard S, Pupa SM, Colzani E et al. Humoral immune response against the neu oncoprotein in patients with breast carcinoma. In Lemoine N, Epenetos A (eds): Mutant Oncogenes: Targets for Therapy? London: Chapman & Hall Medical 1993; 21-6.
52. Disis ML, Calenoff E, McLaughlin G et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994; 54: 16-20.
53. Rughetti A, Turchi V, Ghetti CA et al. Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res 1993; 53: 2457-9.
54. Kotera Y, Fontenot JD, Pecher G et al. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994; 54: 2856-60.
55. Croce MV, Price MR, Segal-Eiras A. Expression of monoclonal-antibody-defined antigens in fractions isolated from human breast carcinomas and patients' serum. Cancer Immunol Immunother 1995; 40: 132-7.
56. Real RX, Mattes MJ, Houghton AN et al. Class I (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody. J Exp Med 1984; 160: 1219-33.
57. MacLean GD, Reddish MA, Bowen-Yacyshyn MB et al. Active specific immunotherapy against adenocarcinomas. Cancer Invest 1994; 12: 46-6.
58. MacLean GD, Reddish M, Koganty RR et al. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother 1993; 36: 215-22.
59. Livingston PO. Approaches to augmenting the immunogenicity of melanoma gangliosides: From whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 1995; 145: 147-66.
60. Foon KA, Chakraborty M, John WJ et al. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J Clin Invest 1995; 96: 334-42.
61. Somasundaram R, Zaloudik J, Jacob L et al. Induction of antigen-specific T- and B-cell immunity in colon carcinoma patients by anti-idiotypic antibody. J Immunol 1995; 155: 3253-61.
62. Köhler H, Kaveri S, Kieber-Emmons T et al. Idiotypic networks and nature of molecular mimicry: An overview. Methods Enzymol 1989; 178: 3-35.